Causal insights on targets and populations.

We are building the GPS of drug development, the world's most accurate atlas of AI-driven disease markers to navigate the path to clinical success.

Subscribe to our Blog to stay tuned on Human Evidence.

Latest

Pheiron enters strategic collaboration with Ribocure

This collaboration aims to enhance Ribo’s target discovery capacity in cardiometabolic diseases by integrating advanced human evidence generated through Pheiron’s AI technology.

September 24, 2024

3

min read

Using an ECG-based
AI-Biomarker to assess GLP-1’s Real-World Cardioprotective Benefits

At Pheiron, we use AI to integrate multi-omic data and accurately capture disease pathophysiology accurately in AI-driven biomarkers. One key application of our AI-biomarkers is in enhancing the evidence generated from RCTs and real-world observational studies. Here we validated and applied one of our AI-biomarkers, an algorithm predicting cardiovascular risk from 12-lead ECGs in collaboration with DandelionHealth.

September 18, 2024

5

min read

The GPS for drug development: navigating with evidence from human populations

Stakeholders lack critical evidence on whether their drug target will work in humans before trialing for it, and they lack tools to use insights on target biology to optimize clinical positioning. Human evidence from large populations offers critical insights to navigate and de-risk R&D: ensure target safety and efficacy at the earliest stages and align target biology with the right clinical phenotypes benefitting from target modulation.

September 17, 2024

10

min read

Why Pheiron and Why Now?

Drug development is broken: Over 90% of drug development programs entering clinical development fail, costing the industry an average of $6.16bn for a novel approved drug. The root of the problem? Insufficient evidence to anticipate clinical efficacy. We build Pheiron to change that - in silico and at scale.

February 16, 2024

8

min read

PreferencesLegalPrivacy
Contact us